In a major breakthrough for thyroid and breast cancer care, Huashan Hospital of Fudan University successfully completed Shanghai's first single-port robotic breast cancer mastectomy with immediate reconstruction and the city’s first robotic thyroidectomy using the SHURUI® system.
Led by Prof. Qiang Zou and Prof. Yiting Jin, the surgical team utilized SHURUI®'s flexible snake-like instruments and 3D imaging to perform both complex procedures through a single hidden incision—preserving aesthetics while ensuring oncologic precision. For the breast case, gland removal and reconstruction were completed without visible scarring. In the thyroid case, a subclavicular approach avoided neck incisions altogether.
With over 40 years of experience in breast and endocrine surgery, Huashan Hospital’s innovation reflects a shift toward ultra-minimally invasive, patient-centered solutions. As SHURUI® single-port robotics expands in China, Huashan is advancing individualized, scar-concealed treatment for head, neck, and chest cancers.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
